688317.SH
之江生物
SSE · Healthcare · Biotechnology · CN
CNY 17.17
−2.99%Year over year
Reported trailing growth
- Revenue
- -26.0%
- EBITDA
- —
- EBIT
- +70.7%
- EPS
- +71.9%
- Free cash flow
- -28.0%
- Operating cash flow
- -3.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -62.3%
- EBITDA
- -73.6%
- EBIT
- +67.3%
- Net income
- +73.1%
- EPS
- +71.6%
- Free cash flow
- -49.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026